entertainment -WSS

entertainment

author：focus 2025-09-06 02:28:39 - browse：99

TRENTON, N.J. — Pharma industry giants including Bristol Myers Squibb, Johnson & Johnson, Novartis, and Novo Nordisk deployed a half-dozen lawyers to a courtroom here Thursday in a bid to dismantle Medicare’s new drug price negotiation program, just hours before President Biden is set to glorify it in his State of the Union.

A federal judge in New Jersey heard an unusual quadruple oral argument in which attorneys for all four drugmakers combined forces to challenge different facets of the Inflation Reduction Act, which in 2022 empowered Medicare to negotiate the prices of a small number of drugs each year beginning in 2026.

Over four hours, the debate spanned most of the substantive issues that pharmaceutical companies and their allies have raised across the country, both in constitutional challenges to the law and in challenges to how Medicare officials have interpreted the law so far. That means the court’s decision in these cases could produce a first substantive test for several of the arguments that haven’t been addressed by courts in other states, where companies like Boehringer Ingelheim, AstraZeneca, and Merck are also suing, separately, over the same law.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： STAT series 'Denied by AI' wins major journalism prizes

knowledge

WSS

Hottest summer in 2,000 years puts focus on extreme heat, health

Lilly’s weekly insulin works as well as daily products, new studies show

After decades in use, heart stents finally beat placebo

Publishing genetic code of viruses could cause disaster

Type 2 diabetes prevention programs work at large scale: study

After decades in use, heart stents finally beat placebo

explore

entertainment

focus

How one medical school became remarkably diverse

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

Novavax promises a turnaround & Lilly roils the obesity market

Experimental asthma app from Apple and Anthem shows promise

23andMe had bad news about my health. I wish a person had delivered it

White House drug czar issues call for 'recovery

Supreme Court strikes down use of affirmative action

Ventyx halts psoriasis drug development after lackluster trial results

Medical leaders decry Supreme Court decision on affirmative action

FDA reorg will put new emphasis on investigations, sources say

focus

CVS, Rite Aid closures threaten to worsen pharmacy deserts

Ripples from Flovent's discontinuation is killing children with asthma

The United States must get value

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

STAT reporters are Pulitzer Prize finalists for investigative reporting

A letter from the executive editor: STAT UnitedHealth investigation

knowledge

focus

Wikipedia

leisure time